{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:45:37Z","timestamp":1792860337510,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jacl.2024.09.008","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:36:24Z","timestamp":1731465384000},"page":"83-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-4024","authenticated-orcid":false,"given":"Zahid","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-6624","authenticated-orcid":false,"given":"Ambika","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Baldassarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Chait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1679-2095","authenticated-orcid":false,"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Patni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-6303","authenticated-orcid":false,"given":"Daniel E.","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-0522","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5536","authenticated-orcid":false,"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-2815","authenticated-orcid":false,"given":"Irina","family":"Yermilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-0068","authenticated-orcid":false,"given":"Cynthia","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-642X","authenticated-orcid":false,"given":"Sarah N","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2024.09.008_bib0001","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u201cFCS score","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2024.09.008_bib0002","unstructured":"Familial Chylomicronemia Syndrome (FCS) [Internet]. Endocrine Society. [cited 2022 Oct 13]. Available from: https:\/\/www.endocrine.org\/patient-engagement\/endocrine-library\/familial-chylomicronemia-syndrome."},{"key":"10.1016\/j.jacl.2024.09.008_bib0003","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0004","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2024.09.008_bib0005","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jacl.2024.09.008_bib0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1476-511X-10-157","article-title":"Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study","volume":"10","author":"Sandhu","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2024.09.008_bib0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/011542650401900105","article-title":"The pathophysiology of pancreatitis","volume":"19","author":"Khokhar","year":"2004","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.jacl.2024.09.008_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.10702","article-title":"Diagnosis and management of type i and type V hyperlipoproteinemia","volume":"19","author":"Gotoda","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2024.09.008_bib0009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12944-022-01631-z","article-title":"Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia","volume":"21","author":"Paragh","year":"2022","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2024.09.008_bib0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2014current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0011","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jacl.2018.03.093","article-title":"Clinical and biochemical features of different molecular etiologies of familial chylomicronemia","volume":"12","author":"Hegele","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0014","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOL.0000000000000866","article-title":"Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia","volume":"34","author":"Hang","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0015","doi-asserted-by":"crossref","DOI":"10.20945\/2359-3997000000601","article-title":"Screening program for familial hyperchylomicronemia syndrome detection: experience of a university health system","author":"Masson","year":"2023","journal-title":"Arch Endocrinol Metab [Internet]"},{"key":"10.1016\/j.jacl.2024.09.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117476","article-title":"Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)","volume":"391","author":"Bashir","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2024.09.008_bib0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0018","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1210\/js.2019-00214","article-title":"Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles","volume":"3","author":"O'Dea","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jacl.2024.09.008_bib0019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.yebeh.2018.06.002","article-title":"Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: a Spanish perspective","volume":"86","author":"Tremblay","year":"2018","journal-title":"Epilepsy Behav EB"},{"key":"10.1016\/j.jacl.2024.09.008_bib0020","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.3390\/jcm11154311","article-title":"Identifying patients with familial chylomicronemia syndrome using FCS score-based data mining methods","volume":"11","author":"N\u00e9meth","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2024.09.008_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2024.09.008_bib0022","article-title":"Posicionamento Brasileiro sobre S\u00edndrome da quilomicronemia familiar \u20132023","volume":"120","author":"Izar MC de","year":"2023","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"key":"10.1016\/j.jacl.2024.09.008_bib0024","unstructured":"Fitch K, editor. The Rand\/UCLA appropriateness method user's manual. Santa Monica: Rand; 2001. p 109."},{"key":"10.1016\/j.jacl.2024.09.008_bib0028","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"patients and families living with FCS. Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2024.09.008_bib0029","doi-asserted-by":"crossref","first-page":"bvaa056","DOI":"10.1210\/jendso\/bvaa056","article-title":"Dissection of clinical and gene expression signatures of familial versus multifactorial chylomicronemia","volume":"4","author":"Tremblay","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jacl.2024.09.008_bib0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/ATVBAHA.119.313401","article-title":"Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes","volume":"39","author":"D'Erasmo","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2024.09.008_bib0026","doi-asserted-by":"crossref","first-page":"e13345","DOI":"10.1111\/eci.13345","article-title":"Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic","volume":"50","author":"Rioja","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2024.09.008_bib0027","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000511023","article-title":"Obesity prevalence in the long-term future in 18 European countries and in the USA","volume":"13","author":"Janssen","year":"2020","journal-title":"Obes Facts"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287424002514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:29:20Z","timestamp":1762561760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287424002514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1933287424002514"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.09.008","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}